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http://dx.doi.org/10.1016/j.ccell.2015.07.017SUMMARYThrough in silico and other analyses, we identified FOXC1 as expressed in at least 20% of human AML cases,
but not in normal hematopoietic populations. FOXC1 expression in AML was almost exclusively associated
with expression of the HOXA/B locus. Functional experiments demonstrated that FOXC1 contributes to a
block in monocyte/macrophage differentiation and enhances clonogenic potential. In in vivo analyses,
FOXC1 collaborates with HOXA9 to accelerate significantly the onset of symptomatic leukemia. A FOXC1-
repressed gene set identified in murine leukemia exhibited quantitative repression in human AML in accor-
dance with FOXC1 expression, and FOXC1high human AML cases exhibited reducedmorphologic monocytic
differentiation and inferior survival. Thus, FOXC1 is frequently derepressed to functional effect in human AML.INTRODUCTION
Acute myeloid leukemia (AML) is a hierarchically organized,
clonal neoplastic disorder sustained by a subpopulation of cells
with long-term proliferative potential, often termed leukemia
stem cells (LSCs) (Wiseman et al., 2014). In recent years there
has been a concerted effort to understand the genetic, epige-
netic, and transcriptional differences between AML cells and
their normal cellular counterparts, with the longer term aim of
developing therapeutic strategies that selectively target leuke-
mia cells. One approach has been to prospectively isolate AML
cells with immature progenitor immunophenotypes (immuno-
phenotypic LSCs) and compare their transcriptional profiles
with normal hematopoietic stem and progenitor cells (HSPCs)
(Saito et al., 2010; Kikushige et al., 2010; Goardon et al., 2011).
These studies have highlighted cell surface receptors CD25,
CD32, and HAVCR2 (also known as TIM3) as candidate thera-
peutic targets in AML. These comparative data sets provide aSignificance
Our investigations highlight a frequent pathogenic mechanism
mesenchymal forkhead box transcription factor gene with fu
also highlight FOXC1 as a HOX-collaborating factor. Continue
comb repressive complex 2 (PRC2) dependent, because treat
nificant increases in its expression. However, bioinformatics a
derepression of genes normally marked by Polycomb in CD
locus-specific phenomenon rather than a genome-wide failure
Canrich resource for further exploration of biological processes
active in human AML. Of particular interest is the set of transcrip-
tion factors expressed in AML, in view of their essential roles in
regulation of gene expression and cell fate.
RESULTS
FOXC1 Is Expressed in Human AML
To identify transcription regulators expressed in human AML
HSPCs but not normal HSPCs, we analyzed levels of transcrip-
tion factor genes (Vaquerizas et al., 2009) in three recent data
sets (Saito et al., 2010; Kikushige et al., 2010; Goardon et al.,
2011). Of those exhibiting significantly higher expression in
AML HSPCs versus normal HSPCs, FOXC1 was among the
most highly upregulated in each study (Figures 1A–1C). Others
similarly upregulated included CEBPA, CEBPD, IKZF1, and
IRF8, known to be highly expressed in myeloid cells (Figures
1A–1C). High FOXC1 expression (where probeset expressionin human AML: the tissue-inappropriate derepression of a
nctional consequences and prognostic significance. They
d FOXC1 repression in normal hematopoietic cells is Poly-
ment of CD34+ cells with distinct PRC2 inhibitors led to sig-
nalyses demonstrated that in AML, there is no widespread
34+ cells. Thus FOXC1 derepression in AML represents a
of Polycomb activity.
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Figure 1. Expression of FOXC1 in Human
AML
(A–C) Heatmaps show the most highly upregu-
lated transcription factor genes in the indicated
studies. Transcription factor genes differentially
expressed in AML HSPCs versus normal adult
immunophenotypic BM HSPCs were identified
using an unpaired t test (with p < 0.005) and
were ranked according to the mean fold change
increase in expression (ranking number shown
on the left of each heatmap row). Color scale
indicates the standardized expression level for
each gene. The definition of HSPCs in each study
was (A) CD34+CD38 for both normal (n = 5)
and AML (n = 21) cells; (B) CD34+CD38Lin
for normal cells (n = 5) and CD34+CD38 for
AML cells (n = 12); and (C) CD34+CD38
CD90+CD45RALin for normal cells (n = 5) and
granulocyte-macrophage progenitor (GMP)-like (n = 21), multipotent progenitor (MPP)-like (n = 3), or CD34+CD38CD90CD45RA+ (n = 3) for AML
samples.
(D) Bar chart shows relative expression of FOXC1 in bulk primary human AML samples (n = 29) and prospectively sorted normal human cell populations
(n = 3 separate individuals per cell type; Huang et al., 2014). See also Table S1. CMP, common myeloid progenitor; Eosin, eosinophils; EryB, erythroblast;
HSC, hematopoietic stem cell (CD34+3890+45RALin); Mega, megakaryocytes; MEP, megakaryocyte-erythrocyte progenitor; Mono, monocytes; Neut,
neutrophils. AML sample numbers refer to the Biobank identifier.
(E) Western blot shows expression of FOXC1 in the indicated AML and normal CD34+ cell samples.
See also Figure S1 and Tables S1–S3.values for FOXC1 were among the top 10% for protein-coding
genes values) was observed in 48%, 50%, and 33% of samples
analyzed in each study, respectively (Figures 1A–1C). Thus,
FOXC1 is among the most highly upregulated transcription fac-
tor genes in AML HSPCs.
FOXC1 is a member of the forkhead box family of transcription
factors, which are critical regulators of development and differ-
entiation. In keeping with a requirement for FOXC1 in mesen-
chymal differentiation, Foxc1-null mice die perinatally with
skeletal, cardiac, and renal abnormalities, hydrocephalus, iris
hypoplasia, and open eyelids (Kume et al., 1998). Humans with
inherited haploinsufficiency of FOXC1 due to mutation or dele-
tion exhibit the Axenfeld-Rieger syndrome, characterized by
similar features to the murine knockout (Nishimura et al., 1998;
Kume et al., 1998). High FOXC1 expression is associated with
poor prognosis in breast and liver cancer (Ray et al., 2010; Xia
et al., 2013), and its forced expression promotes an epithelial-
to-mesenchymal transition and enhanced proliferation, migra-
tion, invasion, and drug resistance, through downstream media-
tors such as NF-kB and NEDD9 (Bloushtain-Qimron et al., 2008;
Wang et al., 2012; Xia et al., 2013). Interestingly, Foxc1 is highly
expressed by Cxcl12-expressing adipo-osteogenic progenitors
in mouse bonemarrow (BM), and its deletion ablates hematopoi-
etic stem cell (HSC) niches leading to reduced BM cellularity
(Omatsu et al., 2014).
Deletion of Foxc1 in normal murine BM does not affect hema-
topoiesis (Omatsu et al., 2014), suggesting redundancy or lack
of expression. To determine whether FOXC1 is expressed in
normal human hematopoiesis, we performed quantitative PCR
on flow-sorted populations of BM HSPCs and terminally differ-
entiated cells, including neutrophils and monocytes (Figure 1D)
(Huang et al., 2014). FOXC1 expression was either absent or
detected at very low level. In contrast, FOXC1 transcripts
were detected at a high level (greater than 200-fold increase
over expression levels in the lowest expressing AML sample)330 Cancer Cell 28, 329–342, September 14, 2015 ª2015 Elsevier Inin 5 of 29 (17%) bulk AML blast samples tested (Figure 1D; Ta-
ble S1) and at an intermediate level in 8 of 29 (28%) samples
(20- to 200-fold increase over expression levels in the lowest
expressing AML sample). Increased FOXC1 transcripts in
AML cells led to increased protein expression (Figure 1E), and
FOXC1 protein was not detected in normal human CD34+ cells
(Figure 1E). These data demonstrate that the mesenchymal
transcription factor FOXC1 (which is neither expressed in nor
required for normal hematopoiesis) is frequently highly ex-
pressed in human AML in both the stem/progenitor and bulk
blast compartments.
FOXC1 Expression in Human AML Is Associated with
Mutations in NPM1 and t(6;9)
Our quantitative PCR analysis in bulk AML samples was
confirmed by expression data from two recent studies. FOXC1
was expressed at a high level (i.e., with a probeset expression
value among the top 25% of protein-coding gene values) in
100 of 461 (22%) of presentation samples from a Dutch cohort
of younger adults (aged <60 years) subsequently treated inten-
sively (i.e., with anthracycline and cytarabine-based chemo-
therapy) on the Hemato-Oncologie voor Volwassenen Neder-
land (HOVON) protocols (Figure S1A) (Wouters et al., 2009).
Similarly 36 of 163 (22%) samples selected to be representative
of the genetic range of human AML also exhibited high expres-
sion (Figure S1B) (Cerami et al., 2012; Cancer Genome Atlas
Research Network, 2013). High FOXC1 expression was strongly
associated with intermediate cytogenetic risk, normal karyotype,
and the presence of an NPM1 mutation or a t(6;9) translocation
(Tables S2 and S3). High FOXC1 expression was negatively
associated with good cytogenetic risk, its associated karyo-
types, and the presence of double CEBPA mutations (Table
S2). In the Dutch study high FOXC1 expression was strongly
associated with the presence of FLT3 internal tandem duplica-
tions, but this was not seen in The Cancer Genome Atlas studyc.
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Figure 2. FOXC1 Sustains the Differentiation Block and Clonogenic Potential of Human AML Cells
(A–G) Human THP1 AML cells were infected with a lentivirus targeting FOXC1 for KD (KD3) or a non-targeting control vector (NTC). (A) Bar chart shows mean +
SEM relative transcript expression in KD versus control cells (n = 3). (B) Western blot shows expression of the indicated proteins in the indicated conditions.
(C) Bar chart shows the mean + SEM colony-forming cell (CFC) frequencies of KD cells relative to control cells enumerated after 10 days in semi-solid culture
(n = 4). (D) Bar chart (left) showsmean + SEM percentage of cells positive for the indicated cell surface markers, as determined by flow cytometry analysis 6 days
following the initiation of KD (n = 4). Representative flow cytometry plots (right) are also shown. (E) Representative images of cytospins of cells from (D).
(F) Western blot shows expression of the indicated proteins in the indicated conditions. (G) Bar chart (left) showsmean + SEMCFC frequencies of THP1 AML cells
expressing either FOXC1 SDM3 (for site-directed mutagenesis #3) or a control retroviral vector (MTV) in FOXC1 KD cells relative to control cells. Colonies were
enumerated after 10 days in semi-solid culture (n = 3). Image (right) shows representative colonies, each of which is marked by a white asterisk.
(H) Normal human CD34+ HSPC were infected with the FOXC1 KD3 vector or a non-targeting control. Bar chart (left) shows mean + SEM total and types of CFCs
(n = 3 separate individuals). Colonies were enumerated after 14 days. Image (right) shows representative colonies. BFU-E, burst-forming unit erythroid; CFU-GM,
colony forming unit granulocyte/macrophage; CFU-M, colony forming unit macrophage.
For (A), (C), (D), and (G), *p < 0.05 by unpaired t test. See also Figure S2.(Tables S2 and S3). There was no association of high FOXC1
expression with other recurring mutations in AML (Table S3).
FOXC1 Sustains Clonogenic Potential and
Differentiation Block in AML Cells
To investigate whether FOXC1 expression in AML contributes
functionally to transformation, we performed knockdown (KD)
experiments in human THP1 AML cells, which exhibit both a
t(9;11) translocation, the cytogenetic hallmark of MLL-AF9, and
high FOXC1 expression. FOXC1 KD led to loss of clonogenic po-
tential due to induction of differentiation and G1 arrest (Figures
2A–2E and S2A). Following KD, there was downregulation of
the stem cell marker CD117, upregulation of the myeloid marker
CD11b (Figure 2D), morphological differentiation (Figure 2E), G1
arrest (Figure S2A), and apoptosis (Figure S2B). To confirm that
the observed phenotype was an on-target consequence of
FOXC1 KD, similar experiments were performed in a line consti-
tutively expressing a FOXC1 cDNA engineered by site-directed
mutagenesis to generate KD-resistant transcripts. FOXC1Canforced expression and resistance to KD was confirmed by west-
ern blotting (Figure 2F). Expression of KD-resistant FOXC1 in
FOXC1 KD cells completely prevented loss of clonogenic poten-
tial (Figure 2G). KD of FOXC1 in other FOXC1 expressing AML
cell lines representative of a variety of molecular subtypes
gave similar results (Figures S2C and S2D). In contrast, there
was no reduction in the clonogenic and multilineage differentia-
tion potential of normal human CD34+ cells (which do not
express FOXC1) infected with the same FOXC1 KD construct
(Figure 2H). These data demonstrate that FOXC1 expression in
AML contributes to oncogenic potential by maintaining differen-
tiation block and clonogenic activity.
Expression of FOXC1 Transiently Impairs Myeloid
Differentiation in Normal HSPCs
To investigate the consequences of forced FOXC1 expression in
normal HSPCs, murine CD117+ BM cells were infected with
retroviral vectors (Figure 3A). In serial replating experiments,
we observed a significant but transient myeloid differentiationcer Cell 28, 329–342, September 14, 2015 ª2015 Elsevier Inc. 331
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Figure 3. FOXC1 Transiently Impairs Myeloid Differentiation of Normal HSPCs
(A–E) Murine CD117+ BM cells were infected with FOXC1-expressing or control retroviral vectors and serially replated in vitro. (A) Western blot shows FOXC1
expression in CD117+ BM cells 48 hr following drug selection and 72 hr post-spinoculation. (B) Bar chart shows mean + SEM CFC frequencies at the end of each
round of serial replating (n = 3). *p < 0.001 by unpaired t test. (C) Bar chart (left) showsmean + SEM types of colonies formed in the second round of culture (n = 3).
Image (right) shows representative colonies. (D) Bar chart (left) showsmean + SEM percentage of the indicated cell types in cytospin preparations from the end of
round 1 (n = 3). Representative images (right) are shown. (E) Representative cytospin image of FOXC1+ cells at the end of round 3.
(F–I) Murine CD45.1+ CD117+ BM cells were infected with the indicated retroviral vectors; 106 drug-resistant cells were transplanted into CD45.2+ irradiated
congenic recipients 96 hr following spinoculation. (F) Bar chart showsmean + SEM percentage donor-derived CD45.1+ cells in blood at the indicated times post-
transplantation. *p < 0.05 for comparison of FOXC1+ recipients versus all others, and at each time point, by one-way ANOVA with Fisher’s least significant
difference post hoc test. (G) Bar chart showsmean + SEMpercentage contribution of donor-derived cells to the indicated lineages (myeloid-lineage, Gr-1+ and/or
Mac-1+; B-lineage, CD19+B220+; T-lineage, T cell receptor b+) 4 weeks post-transplantation. *p < 0.001 for comparison of FOXC1+ recipients versus all others by
one-way ANOVA with Fisher’s least significant difference post hoc test. (H) Bar chart shows the mean myeloid/B-lineage ratio of donor-derived CD45.1+ cells in
blood at the indicated times post-transplantation. (I) Survival curve of mice transplanted with cells infected with the indicated vectors (n = 6 or 7 mice per cohort).
See also Figure S3.block and enhanced proliferation in FOXC1-expressing cells
(FOXC1+ cells). In the second round, FOXC1+ cells generated
approximately five times as many colonies as did control cells
(Figure 3B), with a substantially larger number of tightly packed
blast-like colonies and a lower proportion of fully mature macro-
phage colonies (Figure 3C). In keeping with these observations,
FOXC1+ cell populations at the end of the first round contained a
higher proportion of myeloblasts versus mature cells (Figure 3D)
and a higher proportion of cells in the SG2M phase of the cell cy-
cle (Figure S3A). Immunophenotypic analysis demonstrated
lower expression of the myeloid differentiation marker Gr1 and
the monocyte/macrophage marker F4/80 in FOXC1+ cells by
comparison with control cells (Figure S3B). Despite the signifi-
cant second-round differences, the consequences of FOXC1
overexpression were only transient because there was no signif-332 Cancer Cell 28, 329–342, September 14, 2015 ª2015 Elsevier Inicant difference in the clonogenic potential of third-round cells,
with FOXC1+ cells at the end of that round displaying features
of terminal differentiation (Figure 3E).
To investigate the in vivo consequences of FOXC1 expression
in HSPCs, we performed transplantation experiments. Murine
CD117+ HSPCs were infected with retroviral vectors expressing
FOXC1, Meis1, Hoxa9, or an empty vector (hereafter referred to
as FOXC1+, MEIS1+, HOXA9+, and MTV cells, respectively) and
transplanted into irradiated congenic recipients. Meis1 and
Hoxa9 were chosen as comparators because forced expression
ofMeis1 has no effect onBMchimerism, whereas forced expres-
sion of Hoxa9 is sufficient to cause HSC expansion followed by
long latency AML (Thorsteinsdottir et al., 2002). Assessment of
donor:recipient chimerism in the blood of transplanted mice
over 16 weeks demonstrated, as expected, no significantc.
difference between those receiving MEIS1+ cells versus MTV
cells (Figure 3F). Also as expected, mice receiving HOXA9+ cells
exhibited significantly higher levels of donor:recipient chimerism
(Figure 3F). By contrast, at all time points, recipients of FOXC1+
cells exhibited significantly lower donor:recipient chimerism in
blood (the BM was not sampled) (Figure 3F). Four weeks
following transplantation, there was donor-derived multilineage
engraftment in all cohorts, with proportionately similar levels of
myeloid, B, and T lineage engraftment in MEIS1+, HOXA9+,
and MTV recipients. In contrast, in FOXC1+ recipients, there
were significantly higher levels proportionately of myeloid
engraftment and lower levels of B lineage engraftment (Figures
3G and S3C). At the later time points (8, 12, and 16 weeks),
HOXA9+ recipients showed progressive expansion of the
myeloid compartment and a proportionate reduction in T-lineage
engraftment compared with MEIS1+ and MTV recipients (Fig-
ure S3D). FOXC1+ recipients maintained myeloid skewing of
donor-derived cells. Thus, by comparison with MEIS1+ and
MTV control cells, expression of FOXC1 in HSPCs reduces do-
nor:recipient chimerism in blood and skews differentiation to-
ward the myeloid lineage and away from the B cell lineage
(Figure 3H).
In keeping with progressive expansion of the myeloid
compartment, and previous reports (Thorsteinsdottir et al.,
2002), mice transplanted with HOXA9+ cells succumbed to
AML with a median latency of 103 days (Figure 3I), whereas at
the termination of the experiment 200 days post-transplantation,
none of the mice from any other cohort had died of a donor-
derived hematological neoplasm or exhibited any features
thereof in BM analyses (data not shown). The three mice that
did die succumbed to recipient origin T cell leukemia (MTV recip-
ient) or recipient origin T cell lymphoma (MEIS1+ and FOXC1+ re-
cipients). Taken together, these data indicate that expression of
FOXC1 in HSPCs, although not overtly leukemogenic, is suffi-
cient to induce a transient myeloid differentiation block in vitro
and to skew differentiation toward the myeloid lineage in vivo.
FOXC1 Expression in Human AML Is Associated with
High HOX Gene Expression
Given that expression of FOXC1 alone is insufficient to induce
AML, we next investigated whether it might collaborate with
other factors to promote leukemogenesis. To identify transcrip-
tion factor genes whose expression is associated with that of
FOXC1 in human AML, we compared FOXC1high AMLs with
FOXC1low AMLs (Figure S1A and Table S2) (Wouters et al.,
2009) and found HOXA9, HOXA5, and HOXB3 to be the most
highly upregulated genes in the FOXC1high group (Figure S4A).
Notably, high expression of HOX genes is a shared feature of
NPM1-mutated AML and AML with a t(6;9) translocation, poten-
tially explaining the particular association of high FOXC1 expres-
sionwith thesemolecular subtypes. Quantitative PCR (Figure 4A)
and analysis of expression data (Figures 4B and 4C) confirmed
the strong association. By quantitative PCR, all five samples
from our cohort with high FOXC1 expression exhibited high
HOXA9 expression, and 43% of high-HOXA9-expressing AML
samples exhibited high FOXC1 expression (Figure 4A). In the
published studies, 95 of 100 (95%) and 34 of 36 (94%), respec-
tively, with high FOXC1 expression also exhibited high HOXA9
expression (Figures 4B and 4C), and 95 of 320 (30%) and 34 ofCan115 (30%), respectively, of high-HOXA9-expressing AML sam-
ples exhibited high FOXC1 expression (Figures 4B and 4C). Of
the total of seven FOXC1high,HOXA9low cases from both expres-
sion studies, three exhibited high HOXB2, HOXB3, or HOXB4
expression, leaving just 4 of 129 (3%) of FOXC1high cases across
both studies lacking HOX gene expression.
To examine this association in more detail, 461 AML cases
(Wouters et al., 2009) were grouped into five categories accord-
ing to their pattern of HOX gene expression (Figure S4B). Twelve
HOX genes were expressed at very high level in AML (where at
least 1% of 461 samples exhibited probeset values in the top
10% of protein-coding genes, i.e., >log2 8.3) and unsupervised
analysis of their expression patterns demonstrated three major
clusters: HOXA, HOXB2–6, and HOXB8/9 (Figure S4C). The
karyotypes and mutation spectra of the five groups were as
expected (Figures S4D and S4E) (Wouters et al., 2009). The
FOXC1high cases weremost strongly associated with HOX group
1 (pan-HOXhigh) and to a lesser extent with HOX groups 2
(HOXAhigh/HOXB2–6high/HOXB8–9low) and 3 (HOXAhigh/HOXBlow)
(Figure S4F). This indicates that FOXC1 expression in AML is
strongly associated with high-level expression across the
HOXA and HOXB locus, not just HOXA9. The observation that
approximately 30% of HOXA9-expressing human AML samples
express FOXC1 in a tissue-inappropriate manner suggested that
FOXC1 collaborates with HOX family transcription factors to
enhance leukemogenesis.
FOXC1 Expression Collaborates with Hoxa9 Expression
to Enhance Clonogenic Potential and Differentiation
Block and Accelerate the Onset of Symptomatic
Leukemia
To investigate this question further, murine CD117+ HSPCs were
infected in pairwise combinations with retroviral vectors ex-
pressing Hoxa9, FOXC1, Meis1, or a control vector (to generate
Hoxa9/MTV, Hoxa9/FOXC1, and Hoxa9/Meis1 cells, respec-
tively), and their clonogenic potential was assessed in serial re-
plating assays. MEIS1 is an established HOXA9 cofactor (Kroon
et al., 1998). As expected, Hoxa9 expression induced sustained
clonogenic activity of BMHSPCs in serial replating assays, an ef-
fect enhanced byMeis1 (Figure 4D). Interestingly, co-expression
of FOXC1 with Hoxa9 significantly enhanced the clonogenic ac-
tivity of BM HSPCs versus cells expressing Hoxa9 alone (Fig-
ure 4D). Hoxa9/FOXC1 co-expression also significantly
enhanced differentiation block by comparison with cells ex-
pressing Hoxa9 alone: by the fourth round of culture, Hoxa9/
FOXC1 cells formed approximately four times more type I col-
onies (which contain poorly differentiated myeloid cells) (Figures
4D–4F), displayed more blast cells in cytospin preparations (Fig-
ure 4G), and expressed significantly lower levels of both the
mature myeloid marker Gr1 and the monocyte/macrophage
marker F4/80 (Figures 4H and 4I).
To determine whether HOXA9 and FOXC1 collaborate in
leukemogenesis, Hoxa9/MTV, Hoxa9/FOXC1, and Hoxa9/
Meis1 double-transduced HSPCs were transplanted into irradi-
ated congenic recipients. Levels of donor:recipient chimerism
in blood at 4 and 8 weeks post-transplantation were lower in
Hoxa9/FOXC1 recipients than in the other two cohorts (Fig-
ure 5A). Donor-derived multilineage engraftment was observed
in all three cohorts at both time points (Figures 5B and S5A).cer Cell 28, 329–342, September 14, 2015 ª2015 Elsevier Inc. 333
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Figure 4. FOXC1 Collaborates with HOXA9 to Enhance Clonogenic Potential and Differentiation Block in BM HSPCs
(A–C) Scatterplots show the expression of FOXC1 versus HOXA9 in primary AML patient samples as determined by (A) quantitative PCR (n = 29; see also Table
S1) or (B and C) array expression values from the indicated studies. Percentages in blue text indicate proportion of FOXC1high samples exhibiting high HOXA9
expression. Percentages in red text indicate the proportion ofHOXA9high samples (in the red box) additionally exhibiting high FOXC1 expression (above the dotted
gray line).
(D) Bar chart shows mean + SEM CFC frequencies after each round of serial replating of murine CD117+ BM cells co-transduced with the indicated retroviral or
control expression vectors (n = 3).
(E) Bar chart shows mean + SEM frequencies of colony types after the fourth round of serial replating (n = 3). Type I colonies contain poorly differentiate my-
eloblasts, type II colonies contain a mixed population of blasts and differentiating myeloid cells, and type III colonies contain terminally differentiated myeloid
cells. For (D) and (E), *p < 0.05 by one-way ANOVA with Fisher’s least significant difference post hoc test.
(F and G) Representative images show (F) colonies and (G) cytospin preparations from the end the fourth round of replating.
(H) Bar chart shows mean + SEM percentage of cells positive for the indicated cell surface markers (as determined by flow cytometry) following 6 days in liquid
culture (n = 3). *p < 0.001 by one-way ANOVA with Fisher’s least significant difference post hoc test.
(I) Representative flow cytometry plots of cells shown in (H).
See also Figure S4.However, as with the single transduction transplants (Figures 3G
and 3H), there were significantly higher levels proportionately of
myeloid engraftment, and lower levels of B-lymphoid engraft-
ment, among recipients of Hoxa9/FOXC1 cells by comparison
with mice receiving eitherHoxa9/MTV orHoxa9/Meis1 cells (Fig-
ures 5B, 5C, and S5A).
As expected, recipients of Hoxa9/Meis1 cells developed AML
more rapidly than recipients of Hoxa9/MTV cells (median 57334 Cancer Cell 28, 329–342, September 14, 2015 ª2015 Elsevier Inversus 125 days; Figure 5D). Strikingly, despite lower donor:reci-
pient chimerism in the blood in the initial post-transplantation
period, recipients of Hoxa9/FOXC1 cells also succumbed to
AML substantially earlier than mice receiving Hoxa9/MTV cells
(83 versus 125 days; Figure 5D). By comparison with Hoxa9/
MTV or Hoxa9/Meis1 recipients, at the point of death, Hoxa9/
FOXC1 recipients exhibited significantly lower total circulating
leukocyte counts, although 30%–40% of these were blastsc.
(Figures 5E, 5F, and S5B). However, Hoxa9/FOXC1 recipients
exhibited much more extensive tissue infiltration with blasts
than mice from other cohorts, with high-level donor:recipient
chimerism in BM and spleen (Figures S5C and S5D). Thus, a
key feature of the Hoxa9/FOXC1 murine AMLs was failure of
AML blasts to mobilize substantially to the blood despite high-
level involvement of BM, liver, and spleen. In the BM, Hoxa9/
FOXC1 recipients exhibited significantly higher blast percent-
ages, significantly higher CD117 expression, and significantly
lower F4/80 expression (Figures 5G–5J). In each cohort and in
each case, autopsy demonstrated splenomegaly and hepato-
megaly, with spleen weights being significantly higher in
Hoxa9/FOXC1 recipients than both other cohorts and liver
weights being significantly higher in Hoxa9/FOXC1 recipients
versus Hoxa9/Meis1 recipients (Figure S5D). Histological anal-
ysis of spleen demonstrated that in Hoxa9/MTV and Hoxa9/
Meis1 recipients, the splenic architecture was maintained with
preservation of the white pulp. The red pulp, however, was
expanded by sheets of blast cells, with scattered normal mega-
karyocytes and erythroid precursors indicating residual but ex-
tramedullary hematopoiesis. By comparison, in Hoxa9/FOXC1
recipients, the splenic architecture was completely effaced by
blasts (Figure S5E). In the livers of Hoxa9/MTV and Hoxa9/
Meis1 recipients, there was periportal and perivenular accumu-
lation of blasts, more extensive in the former than the latter,
with relative sparing of the intervening parenchyma, where only
single and small groups of blasts were seen within sinusoids.
By contrast, inHoxa9/FOXC1 recipients, there was a diffuse infil-
trate of blasts, forming small clusters that expanded the sinu-
soids. Periportal and perivenular blasts, although present, were
less conspicuous than those seen in mice from the other cohorts
(Figures S5F and S5G). Cell-cycle analysis of AML cells from
both BM and spleen demonstrated a significantly higher fraction
of cycling cells in Hoxa9/FOXC1 recipients by comparison with
the other cohorts, consistent with a differentiation block at a pro-
liferative progenitor stage (Figures 5K, 5L, and S5H). FOXC1 pro-
tein was expressed in the Hoxa9/FOXC1 AML cells (Figure S5I),
which were also able to initiate leukemia in secondarily trans-
planted recipients with shortened latency (Figure 5M).
Together, these in vitro and in vivo data demonstrate that
FOXC1 collaborates with HOXA9 to increase clonogenic poten-
tial and cell-cycle progression, enhance a monocyte/macro-
phage and B-lineage lineage differentiation block and accelerate
the onset of symptomatic leukemia in mice.
FOXC1 Represses a Monocytic Lineage Differentiation
Program in Leukemic Hematopoiesis
To investigate the consequences of FOXC1 expression on the
transcriptome in murine AML, we next performed exon array
analysis using flow-sorted CD117+Gr1+ leukemia cells recov-
ered from sick mice. Populations with this immunophenotype
are enriched for leukemia-initiating cell activity in Hoxa9/Meis1
murine leukemias (Gibbs et al., 2012). In keeping with the
observed immunophenotypes of the respective leukemias (Fig-
ures 5I and 5J), analysis of protein-coding genes that passed
threshold criteria demonstrated that Hoxa9/FOXC1 AMLs clus-
tered separately from Hoxa9/Meis1 and Hoxa9/MTV AMLs
(which clustered much more closely with one another) (Fig-
ure S6A). Genes with the highest mean differential expressionCan(at least 2-fold) in Hoxa9/FOXC1 AMLs versus the others formed
two groups: group A genes, which were more highly expressed
in theHoxa9/FOXC1 AMLs versus the others, and group B genes
(the larger set), which were repressed (Figure 6A and Table S4).
Gene ontology analysis demonstrated significant enrichment
within the group B gene set of biological process terms such
as ‘‘immune response,’’ ‘‘defense response,’’ and ‘‘inflammatory
response’’ (Table S4), indicating a gene set associated with
myeloid cells involved in inflammation and immunity. At a similar
level of statistical significance, there were no enriched terms
among the group A gene set.
To determine whether FOXC1-regulated gene sets in murine
AML cells were more highly expressed in monocytes or neutro-
phils, we evaluated the relative expression of human homologs
of group A and B genes in exon array data sets from primary hu-
man cells using gene set enrichment analysis (GSEA) (Table S5).
In keeping with reduced expression of the monocyte/macro-
phage marker F4/80 in murine Hoxa9/FOXC1 AML cells (Figures
5I and 5J), this cross-species analysis demonstrated that FOXC1
repressed a monocyte-expressed gene set and promoted
expression of a neutrophil-expressed gene set (Figure 6B).
Also in keeping with the unexpected ability of the mesen-
chyme-expressed transcription factor FOXC1 to repress mono-
cyte differentiation, we observed that phorbol ester treatment of
HL60 AML cells (which express FOXC1) led to substantial down-
regulation of the protein as cells underwent monocytic differen-
tiation, whereas the reverse was the case as cells underwent
granulocytic differentiation following all-trans retinoic acid treat-
ment (Figure S6B).
Next, to determine whether a signature of FOXC1 transcrip-
tional activity could be identified in human AML, and to confirm
the functional relevance of its derepression in human disease,
we evaluated the expression of human homologs of FOXC1-
repressed group B genes in AML using GSEA (Figure 6A and
Table S4). Protein-coding genes in FOXC1high AMLs versus FOX-
C1low AMLs (Wouters et al., 2009) were ranked using a signal-to-
noise ranking metric (Table S5). GSEA demonstrated highly sig-
nificant negative enrichment of FOXC1-repressed group B
genes among FOXC1high AMLs versus FOXC1low AMLs, and
this was observed whether all AMLs were considered (Figure 6C;
n = 461) or just those expressing HOXA9 (Figure 6D; n = 320). In
fact, in leading edge analyses (Table S4), there was a highly sig-
nificant association of higher FOXC1 expression with greater
repression of group B genes (Figure 6E). Remarkably, when
the morphological classification of HOXA9+ AMLs was consid-
ered, among cases with high FOXC1 expression, there were
significantly fewer AMLs of French-American-British (FAB) M4
and M5 subtypes, which exhibit monocytic differentiation, and
significantly more of the FAB M2 subtype, which lack it (Fig-
ure 6F). Furthermore, in this cohort of younger adult AML pa-
tients (aged < 60 years) treated intensively on the Dutch HOVON
protocols, those with FOXC1high AML exhibited significantly infe-
rior survival in comparison with FOXC1low cases, whether all
other AMLs were considered (median 12 versus 32 months) or
only those expressing HOXA9 (median 12 versus 20 months)
(Figure 6G). Indeed, in multivariate analysis (Table S6), high
FOXC1 expression was an independent predictor of inferior sur-
vival in addition to age, cytogenetic risk score, and NPM1/FLT3
mutation status, whether analyzed as a categorical variablecer Cell 28, 329–342, September 14, 2015 ª2015 Elsevier Inc. 335
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Figure 5. FOXC1 Collaborates with HOXA9 to Accelerate Leukemogenesis
Murine CD45.1+ CD117+ BM cells were co-transduced with retroviral vectors. Ninety-six hours later, 106 drug-resistant cells were transplanted into CD45.2+
irradiated congenic recipients.
(A) Bar chart shows mean + SEM percentage of donor-derived CD45.1+ cells in blood at the indicated times post-transplantation.
(B) Bar chart shows mean + SEM percentage contribution of donor-derived cells to each lineage in blood 4 weeks post-transplantation.
(C) Bar chart shows the mean myeloid/B-lineage ratio of donor-derived cells in blood at the indicated times post-transplantation.
(D) Survival curves of transplanted mice (n = 7 per cohort). Median survivals are shown.
(legend continued on next page)
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(Table S6) or a continuous variable (hazard ratio 1.136, 95% con-
fidence interval 1.04–1.24; p = 0.004; rest of model not shown).
These data indicate that in human leukemic hematopoiesis, as
in murine leukemic hematopoiesis, expression of FOXC1 en-
hances a block to monocyte/macrophage differentiation and
leads to inferior survival.
FOXC1 Regulates Expression of KLF4
The transcription factor KLF4 positively regulates monocyte dif-
ferentiation (Feinberg et al., 2007) and exhibits anti-proliferative
and tumor suppressor activity in B cell malignancies (Kharas
et al., 2007). Consistent with our observation that FOXC1 expres-
sion is inversely associated with monocytic morphologic classi-
fication of human AML (Figure 6F) (Wouters et al., 2009), KLF4
expression was significantly lower in FOXC1high human AML
versus FOXC1low AML (Figure 7A). Klf4 expression was also
significantly lower in murine Hoxa9/FOXC1 AMLs in comparison
with Hoxa9/MTV and Hoxa9/Meis1 AMLs (Figure 7B). Function-
ally, in human THP1 AML cells, FOXC1 KD led to KLF4 upregu-
lation (Figure 7C), and in murine CD117+ HSPCs, forced
expression of FOXC1 reduced Klf4 expression, had no effect
on expression of Hoxa9, and modestly increasedMeis1 expres-
sion (Figure 7D). Forced expression of KLF4 in murine Hoxa9/
FOXC1 AML cells significantly reduced both clonogenic cell fre-
quencies and colony size (Figures 7E–7G) through reduction of
the proportion of cells in the SG2M phase of the cell cycle. These
data suggest that direct or indirect repression of KLF4 by FOXC1
is one significant contributing factor to the phenotypic appear-
ances of murine and human FOXC1+ AMLs.
Loss of Polycomb-Mediated Repression Promotes
FOXC1 Derepression
In normal human CD34+ HSPC, the FOXC1 gene occupies a
DNA-hypomethylated and histone H3K27-trimethylated region
of the genome (Figures 8A and S7A) (Zhou et al., 2011). Interest-
ingly, despite absent or very low level expression, the locus
exhibits hypersensitivity to DNase treatment, as well as the pres-
ence of histone H3K4 methylation marks and acetylation of H2A,
H2B, H3, and H4 histones, suggesting a lack of chromatin
compaction (Figures 8A and S7A). In K562 leukemia cells,
FOXC1 is also not expressed and sits in chromatin with similar
features to that seen in CD34+ cells. Importantly, there is signif-
icant binding of Polycomb repressive complex (PRC) 2 compo-
nents EZH2 and SUZ12 across the locus correlating with the
presence of H3K27 trimethyl marks. In addition, there are also
co-localized binding peaks of PRC1 components RNF2, CBX2,(E and F) Bar charts showmean + SEM (E) total blood leukocyte count and (F) perc
by hemocytometer counting and morphologic analysis of blood smears respecti
(G) Bar chart shows mean + SEM percentage cell type in BM at death (n = 3–5 p
(H) Representative images from (G).
(I) Bar chart shows the mean + SEM percentage of donor-derived cells positive fo
flow cytometry.
(J) Representative flow cytometry plots from (I).
(K) Mean + SEM percentage of BM cells in the indicated phase of the cell cycle
(L) Representative profiles from (K).
(M) Survival curves of sub-lethally (4.5 Gy) irradiated mice secondarily transplante
cells are shown for comparison.
For (A), (B), (E), (G), (I), and (K), *p < 0.01 by one-way ANOVAwith Fisher’s least sign
of the others. See also Figure S5.
Canand CBX8 (Figure S7B). In HeLa cells in which FOXC1 is ex-
pressed, EZH2 binding to the locus is absent (Figure S7C). These
data raise the possibility that in normal hematopoietic cells, tran-
scriptional silence of FOXC1 is maintained by PRC.
To address this, we treated normal human CD34+ cells from
multiple donors with PRC inhibitors. Cells treated with the
EZH2 inhibitor GSK343 (Verma et al., 2012) exhibited a signifi-
cant increase in expression of FOXC1 but not HOXA9, which
lacks significant H3K27 trimethylation in CD34+ cells (Figures
8A and 8B). In separate experiments, cells treated with
UNC1999, a dual EZH1 and EZH2 inhibitor (Konze et al., 2013),
exhibited a more extensive fold increase in FOXC1 expression,
but again, expression of HOXA9 was unaffected. PRT4165, a
PRC1 E3 ubiquitin ligase inhibitor (Ismail et al., 2013), modestly
enhanced FOXC1 but not HOXA9 expression (Figure 8C). These
data indicate that continued repression of FOXC1 in the hemato-
poietic system is mediated by PRC2 and imply that loss of its
activity at this genomic locus contributes to its derepression
in AML.
To ascertain whether derepression of silenced, Polycomb-
marked transcription factor genes is widespread in AML or a lo-
cus-specific phenomenon, we identified the set of transcription
factor genes exhibiting a similar epigenetic and transcriptional
pattern to FOXC1 in normal CD34+ cells (i.e., minimally or not ex-
pressed and with high H3K27 trimethylation) using ENCODE
data (n = 253 genes; Table S7) (Zhou et al., 2011). Of the 230
genes represented by probesets on the U133 Plus 2.0 array,
only three (IRX3, IRX5, and HOXB8) were both expressed signif-
icantly in AML (i.e., in the top 20% of probesets in at least 5% of
461 cases) and unexpressed in mature blood cell lineages (as
determined by RNA sequencing of peripheral blood mononu-
clear cells; Zhou et al., 2011). The Iroquois homeobox factors
IRX3 and IRX5 have roles in skeletal, cardiac and neural develop-
ment. Although there was a strong positive association of
increased expression of each of these factors with high FOXC1
expression (Figures 8D, S7D, and S7E), and in particular IRX3
(Figure 8E), the correlation was not absolute. Thus, tissue-inap-
propriate expression of FOXC1 in human AML is a locus-specific
phenomenon rather than part of a generalized failure of Poly-
comb-mediated silencing of repressed genes.
Finally, we considered the possibility that FOXC1 derepres-
sion might be associated with mutations in Polycomb complex
components, or intergenic mutations close to FOXC1 that intro-
duce an enhancer element, as has recently been reported for
TAL1 in T-acute lymphoblastic leukemia (Mansour et al., 2014).
There was no association of FOXC1 expression in AML withentage leukocyte type in blood at death in the indicated cohorts, as determined
vely (n = 3–5 per cohort).
er cohort).
r the indicated cell surface markers in BM of leukemic mice, as determined by
at death.
d with 105 Hoxa9/FOXC1 AML cells. Results of primary transplantations of 106
ificant difference post hoc test for comparison of FOXC1+ samples versus each
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Figure 6. FOXC1 Represses a Monocyte/Macrophage Differentiation Program in Murine and Human AML
(A) Cluster analysis of 567 protein-coding genes that passed threshold criteria (expressed [log2 expression value > 4.1] and with significantly different expression
levels [p < 0.05, unpaired t test and >2-fold difference] in at least one of the two pairwise comparisons between Hoxa9/FOXC1 AMLs versus the others).
(legend continued on next page)
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Figure 7. FOXC1 Regulates KLF4
(A and B) Bar charts show (A) mean + SD log2 array expression value forKLF4 inHOXA9-expressing FOXC1
high (n = 95) and FOXC1low (n = 175) human AML cases
from Wouters et al. (2009) and (B) mean + SEM log2 array expression values for Klf4 in the indicated murine leukemias (n = 3 per cohort). Statistical significance
was assessed using respectively an unpaired t test or one-way ANOVA with Fisher’s least significant difference post hoc test.
(C) Bar chart shows mean + SEM relative expression of the indicated genes 72 hr after initiation of FOXC1 KD using construct KD3 or an NTC (n = 3) (see also
Figure 2).
(D) Bar chart shows mean + SEM relative expression of the indicated genes 72 hr after retroviral infection of CD117+ HSPCs with FOXC1-expressing or control
retroviral vectors and 48 hr following drug selection (n = 3) (see also Figure 3).
(E–G) Hoxa9/FOXC1 AML cells were infected with KLF4-expressing or control retroviral vectors and cultured in semi-solid medium. Bar charts show (E) mean +
SEM relative CFC frequencies and (F) mean + SEM cells per colony in KLF4-expressing cells versus controls (n = 3).
For (C)–(F), *p < 0.05 with an unpaired t test for the indicated comparisons. (G) Representative image from (E).mutations in PRC1 or PRC2 components (Table S8), and com-
parison of whole-genome sequencing data (Cancer Genome
Atlas Research Network, 2013) from six patients with high
FOXC1 expression versus six with absent FOXC1 expression re-
vealed no genomic loci ± 1 MB from the transcription start site of
FOXC1 that were consistently altered either by indels or single-
nucleotide variations in either group (Table S9). This indicates
that derepression of FOXC1 in AML is not driven by genetic mu-
tation of Polycomb components or FOXC1 local regulatory
regions.
DISCUSSION
Derepression of FOXC1 is a frequent phenomenon in human
AML, with approximately 20% of cases exhibiting significant
levels of expression (Wouters et al., 2009). Observed frequencies(B–D) GSEA plots show analyses of enrichment of human homologs of group A an
metric according to expression in (B) primary human neutrophils versus primary
AML samples (Wouters et al., 2009), or (D) HOXA9-expressing FOXC1high (n = 95
(E) Scatterplot shows expression of FOXC1 versusmean log2 expression for the le
(n = 320).
(F) Analysis of morphological classification of HOXA9-expressing FOXC1high (n = 9
the indicated comparisons was assessed using Fisher’s exact test.
(G) Survival curves of patients with FOXC1high versus FOXC1low AML.
See also Figure S6 and Tables S4, S5, and S6.
Canwere higher still in studies focused on the AML stem and progen-
itor compartment (Saito et al., 2010; Kikushige et al., 2010; Goar-
don et al., 2011). More specifically, in bulk AML samples, high
FOXC1 expression is seen in 40% of patients with an NPM1
mutation and50% of those with dual NPM1 and FLT3-ITD mu-
tations (Wouters et al., 2009). The overall frequency of high
FOXC1 expression in human AML exceeds significantly the fre-
quency of mutations in, for example, IDH1 and IDH2 and trans-
locations affecting MLL.
Differentiation block is a characteristic feature of AML, and the
consequence of derepressed FOXC1 expression is to enhance
monocyte/macrophage and B cell lineage blocks, as evidenced
by ourmurine and human functional studies and our bioinformat-
ics analyses. The observation that FOXC1high human AMLs are
less likely to exhibit monocytic lineage morphologic classifica-
tions (i.e., FAB-M4 and M5) and more likely to exhibitd/or group B genes in protein-coding gene lists ranked using a signal-to-noise
human monocytes, (C) FOXC1high (n = 100) versus FOXC1low (n = 290) primary
) versus FOXC1low (n = 175) primary AML samples.
ading edge gene set shown in (D) (see also Table S4) inHOXA9-expressing AML
5) versus FOXC1low (n = 175) primary AML samples. Statistical significance for
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Figure 8. Derepression of FOXC1 in Normal
CD34+ Cells Is Induced by PRC Inhibition
(A) Image shows high-throughput sequencing
tracks from the ENCODE consortium for the HOXA
locus and FOXC1.
(B and C) CD34+ cells from separate normal donors
(n = 3 and 4, respectively) were treated for 4 or
5 days respectively with PRC inhibitors in serum-
free liquid culture. Graphs show expression of
FOXC1 and HOXA9 following treatment with the
indicated inhibitors.
(D) Table shows numbers of HOXA9-expressing
FOXC1high and FOXC1low AML cases fromWouters
et al. (2009), which also expressed IRX3, IRX5, or
HOXB8 (at log2 expression value > 7.1). Statistical
significance for the indicated comparisons was
assessed using Fisher’s exact test.
(E) Scatterplot shows expression of FOXC1 versus
IRX3 in 320 cases of HOXA9-expressing AML.
See also Figure S7 and Tables S7, S8, and S9.morphological classifications associated with granulocyte differ-
entiation (i.e.FAB-M2) is particularly significant and suggests
that derepressed FOXC1 influences morphologic differentiation
in human AML.
The near exclusive association of high FOXC1 expression with
high HOXA/B locus expression in human AML suggests that
FOXC1 collaborates with HOX to enhance leukemogenesis.
This suggestion is confirmed by ourmurine in vitro and in vivo an-
alyses, which show that co-expression of FOXC1withHoxa9 en-
hances clonogenic potential and proliferation, significantly
shortens leukemic latency, and generates leukemias with patho-
logic features that are distinct from those seen in Hoxa9/MTV
and Hoxa9/Meis1 AMLs. Critically, patients exhibiting high
FOXC1 expression levels also exhibit inferior survival, empha-
sizing the prognostic significance of derepression at this locus.
The association of FOXC1 expression with HOX locus expres-
sion implies either that FOXC1 only exerts its phenotypic effects
in the presence of HOX or that HOX transcription factors are
required for expression of FOXC1, or both. In favor of the former
are our observations that forced expression of FOXC1 in murine
CD117+ HSPC fails to upregulateHoxa9 expression and induces
only a transient myeloid differentiation block with enhanced clo-
nogenic potential. In this setting, presumably as HOX gene
expression is downregulated during the course of normal differ-
entiation, FOXC1 loses its collaborating partner(s) and the
phenotype is extinguished. By contrast in AML, where HOX
gene expression is sustained through multiple mechanisms,
FOXC1 exerts its phenotypic effects continuously. Of note, the
cyclin-dependent kinase inhibitor gene CDKN1A (coding for
p21) is one of the group B genes repressed by FOXC1 in murine
leukemias, suggesting a potential mechanism for the enhanced
clonogenic potential of Hoxa9/FOXC1 double-transduced cells
and accelerated onset of AML. It is interesting that FOXC1
expression in AML collaborates with the consequence of a num-340 Cancer Cell 28, 329–342, September 14, 2015 ª2015 Elsevier Inc.ber of distinct genetic mutations (i.e.,
high-level HOX gene expression) rather
than any specific mutation subset in
exclusivity.Our observations that FOXC1 blocks monocytic lineage (and
in vivo B-lineage) differentiation, and that it collaborates with
HOXA9 to enhance clonogenic potential, emphasize that dere-
pression of this mesenchymal transcription regulator in the he-
matopoietic system has hematologic rather than mesenchymal
consequences. This is despite its lack of expression in normal
hematopoiesis. There was, for example, no whole-scale upre-
gulation of a mesenchymal gene program in the Hoxa9/
FOXC1 murine AMLs, although Vcam1 was one notable excep-
tion (Table S4). Expression of this vascular adhesion molecule
may explain the relative failure of murine Hoxa9/FOXC1 AML
cells to mobilize to the blood by comparison with Hoxa9/MTV
and Hoxa9/Meis1 AML cells. Indeed some genes, such as
FN1 and VIM, which are induced by ectopic FOXC1 expression
in breast cancer cells (Bloushtain-Qimron et al., 2008), are
repressed by FOXC1 in murine leukemia cells. Our findings
differ significantly from observations in solid tumors such as
those of the liver, pancreas, and breast, in which FOXC1 has
been causally implicated in promotion of the epithelial-to-
mesenchymal transition characteristic of metastasis (Bloush-
tain-Qimron et al., 2008; Xia et al., 2013; Yu et al., 2013). In
these studies, induced FOXC1 expression has the expected ac-
tivity of a mesenchymal regulator: promotion of mesenchymal
cellular phenotypes such as enhanced migration, invasion,
and metastasis. In AML, by contrast, tissue-inappropriate
expression of FOXC1 interferes with normal tissue activity by
blocking differentiation and enhancing proliferation rather than
conferring on it a mesenchymal phenotype.
This raises the question as to how FOXC1 blocks monocytic
differentiation in AML. One possibility is that it acts as a domi-
nant-negative inhibitor of one or more forkhead transcription
factors whose normal function is to promote monocyte differen-
tiation, although none are directly known to date. Although
diverse forkhead box transcription factors exhibit highly
conserved central DNA binding forkhead domains, they have
very different flanking and transactivation sequences (Lam
et al., 2013). ENCODE RNA sequencing data demonstrate
that a number of forkhead factors are expressed in normal hu-
man CD14+ monocytes, including FOXJ3, FOXP1, FOXN3,
FOXO1, and FOXO3. An alternative possibility is that FOXC1
directly represses through localized binding expression of
one or more key transcriptional regulators of monocytic differ-
entiation. For example, expression of Egr1, Klf4, and Mef2c is
significantly suppressed in Hoxa9/FOXC1 AML cells, and all
these genes code for critical positive regulators of monocyte
differentiation (Laslo et al., 2006; Feinberg et al., 2007; Schu¨-
ler et al., 2008). Our functional analyses demonstrate that
FOXC1 represses expression of KLF4 and show that restora-
tion of KLF4 expression in Hoxa9/FOXC1 AML cells inhibits
proliferation and clonogenic potential. Whether FOXC1-medi-
ated gene repression occurs through binding at multiple
enhancer or promoter sites across the genome or more spe-
cifically through interactions with a master regulator such as
PU.1 remains unclear.
The basis for the collaboration of FOXC1 with HOXA9 likewise
remains unclear. The somewhat similar immunophenotypes and
array expression profiles of murine Hoxa9/MTV AMLs versus
Hoxa9/Meis1 AMLs are in keeping with the known function of
MEIS1 in stabilizing the interaction of HOXA9 with DNA (i.e.,
enhancing its potency) (Shen et al., 1997). The fact that Hoxa9/
FOXC1 AMLs appear so different in terms of their immunophe-
notypes, transcriptomes, and histologies implies that FOXC1
may confer on HOXA9 an alternative activity or perhaps misdi-
rect its binding to distinct enhancer sets. The known activity of
forkhead proteins as pioneer transcription factors may be rele-
vant in this regard (Lam et al., 2013).
FOXC1 occupies a DNA-hypomethylated, DNase-hypersen-
sitive genomic locus in CD34+ cells that is marked by both
H3K4 and H3K27 trimethylation. This suggests the chromatin
surrounding this gene is relatively decompacted, and such
epigenetic configurations have previously been termed biva-
lent. Bivalent genes are transcriptionally repressed by Poly-
comb, and in keeping with this, we were able to induce
expression of FOXC1 in normal human CD34+ cells by treat-
ment of cells with inhibitors of PRC. The most effective was
the dual EZH1/EZH2 inhibitor UNC1999, suggesting EZH1
may compensate for loss of activity of EZH2 when a pure
EZH2 inhibitor is used. Nevertheless, the mechanisms
underlying loss of Polycomb repression at a single locus in
AML require further investigation. Of more than 200 genes
with similar chromatin and transcriptional configurations to
FOXC1 in CD34+ cells, only HOXB8, IRX3, and IRX5 were
similarly derepressed in a significant proportion of AML cases,
indicating that although there is locus-specific loss of Poly-
comb activity in a substantial proportion of AML cases, there
is no generalized failure of suppression of Polycomb marked
genes.
Finally, our findings may have therapeutic consequences. For
example, in basal-like breast cancer, high FOXC1 expression
renders cells more susceptible to pharmacological inhibition of
NF-kB (Wang et al., 2012). Further studies may uncover specific
therapeutic targets or approaches in this frequent sub-group of
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